AZACITIDINE
azacitidine 300 mg tablet, 7
AZACITIDINE (13619T)
13619T
Manner of administration:Oral
Restriction
Indication: Acute Myeloid Leukaemia
Treatment phase: Treatment following intensive induction chemotherapy - Initial treatment
Restriction
Indication: Acute Myeloid Leukaemia
Treatment phase: Treatment following intensive induction chemotherapy - Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 14 | # of repeats: 2 | DPMQ: $13,372.66 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Onureg | |||||